United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Pfizer Inc hit a record high on Tuesday for the first time in more than 20 years as shares of COVID-19 vaccine makers have surged amid rising coronavirus cases in the United States.

Pfizer shares hit record high with COVID-19 vaccine stocks on a tear

Pfizer Inc. (NYSE:PFE) shares are trading higher Tuesday alongside other vaccine stocks. Vaccine stocks have seen increased retail interest of late as the COVID-19 delta variant spreads.

What's Next After Pfizer Stock Powers Higher Tuesday?

Shares of Pfizer jumped to a high of $48.57 on Tuesday, more than a dollar higher than its previous record of $47.3 reached in 1999.

Pfizer jumps 6% to eclipse record high reached in 1999 as strength from COVID-19 vaccine continues

The stock price of Pfizer Inc. (NYSE: PFE) increased 2.02% today. This is why it happened.The stock price of Pfizer Inc. (NYSE: PFE) increased 2.02% today.

PFE Stock Price Increased 2.02%: Why It Happened

Moderna

Vir Biotechnology

Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?

3 Vaccine Stocks for the Next Decade

BioNTech SE

Johnson & Johnson

There's major potential for all of these biotech stocks, especially after full FDA approval, but this one stands to be one of the top winners. The post Why These Biotech Stocks Are Soaring appeared first on InvestorPlace.

Why These Biotech Stocks Are Soaring

Yes, the longtime laggard really could be a big winner for investors going forward.

Buying Pfizer Stock Now Could Double Your Money Within 5 Years: Here's How

AbbVie

Air Products and Chemicals

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Bristol-Myers

Chevron

Enterprise Products Partners

Innovative Industrial Properties

PepsiCo

All of them offer attractive dividends and solid growth prospects, too.

Here Are the 12 Best Dividend Stocks I Own Right Now

Eli Lilly

Merck

Novo Nordisk

Novartis

Roche Holding AG

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Here Are the Winners of Cowen's Big Pharma R&D Showdown

The FDA has raised the bar for vaccine makers.

Why COVID Vaccines for Younger Kids Won't Win Authorization as Soon as Expected

Alibaba

Cricut

Marathon Digital Holdings

XPeng

These seven stocks to buy are poised for a rally in the near-term. They're fundamentally strong and could see returns between 10% and 20%.

7 Short-Term Stocks to Buy for a Shot at Some Quick Cash

Pfizer Inc (NYSE: PFE) and Flynn Pharma Ltd have been accused by the U.K.'s competition watchdog of illegally overcharging the National Health Service (NHS) for anti-epilepsy drugs. What Happened: The Competition and Markets Authority (CMA) said that the companies used a loophole to charge unfairly high prices for phenytoin sodium capsules by debranding the drug, known as Epanutin, in 2012 so it would not face price regulation.

UK Competition And Markets Authority Accuses Pfizer Of Illegal Pricing Of Its Epilepsy Drug

It's more about what's on the way than what happened in the second quarter.

What Really Mattered With Pfizer's Q2 Results

Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.

Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar

It might seem to be the case, at least at first glance.

Is BioNTech Contradicting Pfizer About the Need for Booster Doses?

The UK competition watchdog has accused US drug giant Pfizer Inc of abusing its dominant positions to overcharge the National Health Service for vital anti-epilepsy drugs, with prices hiked over 2,000%. Following the price increases by Pfizer and UK distributor Flynn Pharma, spending by the NHS on phenytoin sodium capsules rose to about £50mln in 2013 from around £2mln in 2012, the Competition and Markets Authority (CMA) said.

Pfizer accused of abusing market position to overcharge NHS with 1,600% price hikes

The new initiative will "best protect the health and safety of our colleagues and the communities we serve," Pfizer said in a statement to CNBC.

Pfizer will require U.S. employees to get Covid vaccine or undergo weekly testing

Advanced Micro Devices

Shares of Pfizer Inc. (NYSE:PFE) and Advanced Micro Devices, Inc. (NASDAQ:AMD) have gone parabolic. This means they have broken out and made huge gains in just a few days.

2 Hot Stocks Go Parabolic: Are Shares About To Be Slapped Down?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2 Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 perc

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Investors should look beyond the company's COVID-19 vaccine.

1 Major Takeaway From Pfizer's Blowout Second-Quarter Results

The global tally for the coronavirus-borne illness headed above 199.6 million on Wednesday, while the death toll climbed above 4.24 million according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 35.2 million cases and in deaths with 614,295 as the highly infectious delta variant continues to spread fast, especially in states with low vaccination rates.

Coronavirus tally: Global cases of COVID-19 near 200 million and FDA seeks full approval of Pfizer vaccine by Labor Day

The stock price of Pfizer has seen an 11% rise over the last twenty-one trading days, and most of the gains have come over the last ten trading days, after the company reported strong Q2 results, and revised its full-year outlook upward. Note that such a move for PFE stock is uncommon, and it has.

Pfizer Stock Has Risen 11% In A Month But Will The Gains Continue?

The chair of Thailand's Thonburi Healthcare Group (THG) said on Wednesday that a deal to import 20 million doses of the Pfizer-BioNTech COVID-19 vaccine was unlikely to happen, despite his earlier claims that a deal was close.

Thai hospital tycoon who promised Pfizer vaccine says deal now unlikely

The U.S. Food and Drug Administration is looking to grant full approval to the Pfizer Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) COVID-19 vaccine by early September, the New York Times reported Tuesday, citing people involved in the effort. What Happened: The FDA is looking at a full approval of the vaccine by Labor Day or sooner, even as President Joe Biden said he expected a full approval in early fall, as per the report.

FDA Looks To Grant Full Approval To Pfizer's COVID-19 Vaccine By Early September: NYT

The Food and Drug Administration says it's engaged in an “all-hands-on-deck approach” to granting full approval to Pfizer's coronavirus vaccine.

News for Pfizer Stock (PFE)